GENOMICS LIMITED

08839972
Active Oxford

Research and experimental development on biotechnology

120 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
G

GENOMICS LIMITED

08839972

Research and experimental development on biotechnology

Founded 10 Jan 2014 Active Oxford, United Kingdom 120 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

GENOMICS PLC 30 Mar 2015 — 7 Nov 2024
GENOMICS LIMITED 10 Jan 2014 — 30 Mar 2015
Accounts Submitted 27 Dec 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 27 Oct 2025 Next due 10 Nov 2026 4 months remaining
Net assets £27M £24M 2024 year on year
Total assets £32M £22M 2024 year on year
Total Liabilities £6M £2M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

King Charles House Park End Street Oxford OX1 1JD United Kingdom

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for GENOMICS LIMITED (08839972), an active life sciences and medical technology company based in Oxford, United Kingdom. Incorporated 10 Jan 2014. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type group
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2022–2024)

Cash in Bank

£23.49M

Increased by £18.57M (+377%)

Net Assets

£26.58M

Increased by £24.31M (+1069%)

Total Liabilities

£5.66M

Decreased by £2.44M (-30%)

Turnover

£11.14M

Increased by £5.50M (+98%)

Employees

120

Increased by 2 (+2%)

Debt Ratio

18%

Decreased by 60 (-77%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 3

Investors (12)

Investor NameInvestor SinceParticipating Rounds
Investor 2Aug 2018Unknown/Other, Series B
Investor 4Aug 2018Unknown/Other, Series B
Investor 5Aug 2018Series B

Share Capital

Share Capital

Share allotments and capital structure

37 Allotments 16,105,920 Shares £79.72m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
25 Nov 20252,300£9k£3.82
7 Nov 2025940£2k£2.55
7 Nov 2025940£2k£2.55
11 Aug 20252,382£9k£3.82
29 Apr 2025533£868.79£1.63

Officers

Officers

2 active 1 resigned
Status
Jose-carlos Gutierrez-ramosDirectorAmericanUnited States636 Nov 2024Active
Simon DingemansDirectorBritishUnited Kingdom637 Sept 2022Active

Shareholders

Shareholders (81)

Csc Employee Benefit Trustee (jersey) Limited
10.3%
1,943,554
Vertex Pharmaceuticals Incorporated
6.2%
1,166,667

Persons with Significant Control

Persons with Significant Control (0)

No PSC information available

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

2 leasehold 2 total
AddressTenurePrice PaidDate Added
Fifth floor premises, 50-60 Station Road, Cambridge (CB1 2JH) CAMBRIDGE
Leasehold-8 Jul 2019
Ground Floor Offices, King Charles House, Park End Street, Oxford (OX1 1JD) OXFORD
Leasehold-31 Dec 2015
Fifth floor premises, 50-60 Station Road, Cambridge (CB1 2JH)
Leasehold
Added 8 Jul 2019
District CAMBRIDGE
Ground Floor Offices, King Charles House, Park End Street, Oxford (OX1 1JD)
Leasehold
Added 31 Dec 2015
District OXFORD

Documents

Company Filings

DateCategoryDescriptionDocument
8 May 2026OfficersTermination of Samuel Cameron Williams as director on 7 May 2026
7 May 2026OfficersAppointment of Mr Gregory Simon Smith as director on 6 May 2026
27 Dec 2025AccountsAnnual accounts made up to 31 Dec 2024
25 Nov 2025CapitalAllotment of shares (GBP 189,292.32) on 25 Nov 2025
17 Nov 2025CapitalAllotment of shares (GBP 189,269.32) on 7 Nov 2025
8 May 2026 Officers

Termination of Samuel Cameron Williams as director on 7 May 2026

7 May 2026 Officers

Appointment of Mr Gregory Simon Smith as director on 6 May 2026

27 Dec 2025 Accounts

Annual accounts made up to 31 Dec 2024

25 Nov 2025 Capital

Allotment of shares (GBP 189,292.32) on 25 Nov 2025

17 Nov 2025 Capital

Allotment of shares (GBP 189,269.32) on 7 Nov 2025

Recent Activity

Latest Activity

Termination of Samuel Cameron Williams as director on 7 May 2026

1 months ago on 8 May 2026

Appointment of Mr Gregory Simon Smith as director on 6 May 2026

1 months ago on 7 May 2026

Annual accounts made up to 31 Dec 2024

5 months ago on 27 Dec 2025

Allotment of shares (GBP 189,292.32) on 25 Nov 2025

6 months ago on 25 Nov 2025

Allotment of shares (GBP 189,269.32) on 7 Nov 2025

7 months ago on 17 Nov 2025